Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors.

Monk JP, Villalona-Calero M, Larkin J, Otterson G, Spriggs DS, Hannah AL, Cropp GF, Johnson RG, Hensley ML.

Invest New Drugs. 2012 Aug;30(4):1676-83. doi: 10.1007/s10637-011-9731-4. Epub 2011 Aug 9.

2.

A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.

Plummer R, Woll P, Fyfe D, Boddy AV, Griffin M, Hewitt P, Carmichael J, Namouni F, Cohen M, Verrill M.

Clin Cancer Res. 2008 Dec 15;14(24):8288-94. doi: 10.1158/1078-0432.CCR-08-0471.

3.

A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer.

Forster M, Kaye S, Oza A, Sklenar I, Johri A, Cheung W, Zaknoen S, Gore M.

Clin Cancer Res. 2007 Jul 15;13(14):4178-84.

4.

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.

Lam ET, Goel S, Schaaf LJ, Cropp GF, Hannah AL, Zhou Y, McCracken B, Haley BI, Johnson RG, Mani S, Villalona-Calero MA.

Cancer Chemother Pharmacol. 2012 Feb;69(2):523-31. doi: 10.1007/s00280-011-1724-7. Epub 2011 Aug 27.

5.

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.

Heath EI, Blumenschein GR Jr, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G.

Cancer Chemother Pharmacol. 2011 Sep;68(3):703-12. doi: 10.1007/s00280-010-1536-1. Epub 2010 Dec 8.

6.

Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.

Dudek AZ, Larson T, Keshtgarpour M, Kumar P.

Am J Clin Oncol. 2007 Oct;30(5):481-6.

PMID:
17921707
7.

Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.

Patnaik A, Wood D, Tolcher AW, Hamilton M, Kreisberg JI, Hammond LA, Schwartz G, Beeram M, Hidalgo M, Mita MM, Wolf J, Nadler P, Rowinsky EK.

Clin Cancer Res. 2006 Dec 15;12(24):7406-13.

8.

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, Fukino K, Tanigawa T, Nakagawa K.

Invest New Drugs. 2010 Dec;28(6):844-53. doi: 10.1007/s10637-009-9321-x. Epub 2009 Sep 18.

9.

Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.

Eberhardt WE, Mitchell P, Schiller JH, Brown MP, Thomas M, Mills G, Jehl V, Urva SR, De Leo JJ, Gogov S, Papadimitrakopoulou V.

Invest New Drugs. 2014 Feb;32(1):123-34. doi: 10.1007/s10637-013-9958-3. Epub 2013 Apr 12.

PMID:
23579358
10.

Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

Jones SF, Burris HA 3rd, Hainsworth JD, Yardley DA, Raefsky EA, Miranda FT, Kuzur ME, Willcutt NT, White MB, Greco FA.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Review.

PMID:
12800605
11.
12.

Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer patients: a phase I study of two sequences.

Ando M, Saka H, Ando Y, Minami H, Kuzuya T, Yamamoto M, Watanabe A, Sakai S, Shimokata K, Hasegawa Y.

Cancer Chemother Pharmacol. 2005 Jun;55(6):552-8. Epub 2005 Mar 15.

PMID:
15856233
13.

Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.

Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH.

Clin Cancer Res. 2009 Jul 1;15(13):4475-83. doi: 10.1158/1078-0432.CCR-08-3144. Epub 2009 Jun 16.

14.

Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas.

Salazar R, Plummer R, Oaknin A, Robinson A, Pardo B, Soto-Matos A, Yovine A, Szyldergemajn S, Calvert AH.

Invest New Drugs. 2011 Dec;29(6):1406-13. doi: 10.1007/s10637-010-9488-1. Epub 2010 Jul 10.

PMID:
20623160
15.

A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Gould N, Sill MW, Mannel RS, Thaker PH, Disilvestro P, Waggoner S, Yamada SD, Armstrong DK, Wenzel L, Huang H, Fracasso PM, Walker JL.

Gynecol Oncol. 2012 Apr;125(1):54-8. doi: 10.1016/j.ygyno.2011.12.417. Epub 2011 Dec 11.

16.

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.

Awada A, Dumez H, Aftimos PG, Costermans J, Bartholomeus S, Forceville K, Berghmans T, Meeus MA, Cescutti J, Munzert G, Pilz K, Liu D, Schöffski P.

Invest New Drugs. 2015 Jun;33(3):611-20. doi: 10.1007/s10637-015-0223-9. Epub 2015 Mar 22.

17.

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.

Patnaik A, Warner E, Michael M, Egorin MJ, Moore MJ, Siu LL, Fracasso PM, Rivkin S, Kerr I, Litchman M, Oza AM.

J Clin Oncol. 2000 Nov 1;18(21):3677-89.

PMID:
11054441
18.

Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.

Tassinari D, Drudi G, Panzini I, Pasini G, Arcangeli V, Fochessati F, Gianni L, Mianulli AM, Oliverio G, Pasquini E, Sartori S, Ravaioli A.

Int J Clin Oncol. 2001 Dec;6(6):279-83.

PMID:
11828946
19.

A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.

Leiser AL, Maluf FC, Chi DS, Sabbatini P, Hensley ML, Schwartz L, Venkatraman E, Spriggs D, Aghajanian C.

Int J Gynecol Cancer. 2007 Mar-Apr;17(2):379-86.

PMID:
17362316
20.

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).

Tran HT, Zinner RG, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS.

Invest New Drugs. 2011 Jun;29(3):499-505. doi: 10.1007/s10637-009-9380-z. Epub 2010 Jan 22.

PMID:
20094773

Supplemental Content

Support Center